# A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection

> **NCT06159062** · PHASE1 · TERMINATED · sponsor: **Yangshengtang Co., Ltd** · enrollment: 1 (actual)

## Conditions studied

- Chronic Hepatitis B Virus Infection

## Interventions

- **DRUG:** 162
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06159062
- **Lead sponsor:** Yangshengtang Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-06-03
- **Primary completion:** 2024-07-09
- **Final completion:** 2024-07-09
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Enrollment difficulty
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06159062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06159062, "A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06159062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*